BridgeBio Pharma BBIO
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9
- Form
- 8-K
- Filed
- Importance
- Routine
- Accession
- 0001140361-26-011991
- Discloses other events (8.01)
Not explained yet; the original is on EDGAR.
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Biomarin Pharmaceutical BMRN public float $6.7B, Jun 30, 2025
- Revolution Medicines RVMD public float $6.7B, Jun 30, 2025
- Jazz Pharmaceuticals JAZZ public float $6.3B, Jun 30, 2025
- Corcept Therapeutics CORT public float $6.1B, Jun 30, 2025
- Repligen RGEN public float $6.0B, Jun 30, 2025